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Preclinical studies have suggested that the pancreatic tumor microenvironment both inhibits and promotes tumor
development and growth. Here we establish the role of stromal fibroblasts during acinar-to-ductal metaplasia (ADM),
an initiating event in pancreatic cancer formation. The transcription factor V-Ets avian erythroblastosis virus
E26 oncogene homolog 2 (ETS2) was elevated in smooth muscle actin–positive fibroblasts in the stroma of
pancreatic ductal adenocarcinoma (PDAC) patient tissue samples relative to normal pancreatic controls. LSL-KrasG12D/+;
LSL-Trp53R172H/+; Pdx-1-Cre (KPC) mice showed that ETS2 expression initially increased in fibroblasts during ADM and
remained elevated through progression to PDAC. Conditional ablation of Ets-2 in pancreatic fibroblasts in a KrasG12D-
driven mouse ADM model decreased the amount of ADM events. ADMs from fibroblast Ets-2–deleted animals had
reduced epithelial cell proliferation and increased apoptosis. Surprisingly, fibroblast Ets-2 deletion significantly altered
immunecell infiltration into the stroma,with an increasedCD8+T-cell population, anddecreasedpresenceof regulatory
T cells (Tregs), myeloid-derived suppressor cells, andmaturemacrophages. Themechanism involved ETS2-dependent
chemokine ligand production in fibroblasts. ETS2 directly bound to regulatory sequences for Ccl3, Ccl4, Cxcl4, Cxcl5,Any opinions, findings, and conclusions expressed in this material are those of the
authors and do not necessarily reflect those of the Pelotonia Fellowship Program.
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542 Fibroblast ETS2 Coordinates ADM Immune Cell Recruitment Pitarresi et al. Neoplasia Vol. 18, No. 9, 2016and Cxcl10, a group of chemokines that act as potent mediators of immune cell recruitment. These results suggest an
unappreciated role for ETS2 in fibroblasts in establishing an immune-suppressive microenvironment in response to
oncogenic KrasG12D signaling during the initial stages of tumor development.
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Pancreatic cancer 5-year survival rates have remained around 5% for
the last 40 years despite efforts to better understand the
underpinnings of this disease [1,2]. Research for the last 2 decades
has concentrated on determining the major oncogenic signaling
pathways within the evolving tumor cell [3–5]. These efforts have
revealed that activating mutations in Kras are early events during
malignant transformation and have suggested that acinar cells are a
potential pancreatic ductal adenocarcinoma (PDAC) cell-of-origin
[6,7]. For example, genetically engineered mouse models demon-
strated that mutant Kras targeted to the acinar lineage is sufficient to
induce pancreatic intraepithelial neoplasia (PanIN) lesions with
ductal morphology [8–10]. Additionally, second-hit mutations, such
as activating Notch mutations, synergize with Kras in acinar cells to
drive ductal reprogramming and PanIN lesion formation [11].
Lineage tracing experiments have shown that acinar cells readily
transdifferentiate into ductal cells (commonly referred to as
acinar-to-ductal metaplasia or ADM) and also demonstrated that
oncogenic Kras mutations in mature acinar cells formed PanINs at a
significantly higher frequency relative to the ductal or centroacinar
cell lineages [12]. This paradigm-shifting study has sparked newfound
interest into the signaling networks that collaborate with Kras to drive
ADM in acini [13–17]. Other reports have solidified the notion that
ADM progresses to PanIN and PDAC and show that ADM occurs in
human PDAC patients [18–21]. During the transformation from
ADM to PanIN to PDAC, there is a concurrent increase in the
desmoplastic reaction that is a cardinal feature of this disease [22–24].
The pancreatic stroma has been scrutinized as a “partner in crime”
for PDAC development, but efforts to elucidate the role of the stroma
in pancreatic cancer to date have relied primarily on in vitro or
transplanted immunodeficient in vivo models of pancreatic cancer
[25–28]. More recent reports have revealed that stromal fibroblasts
are comprised of a heterogeneous population that possesses both pro-
and antitumor characteristics [29–31]. For example, the presence of
smooth muscle actin (SMA)–positive fibroblasts in human PDAC
samples has been correlated with reduced overall survival in one
patient cohort and with increased patient survival in an independent
patient cohort [31,32]. Furthermore, stromal gene expression in 145
human PDAC patient samples revealed two distinct stroma-specific
subtypes (termed normal and activated) with median survivals of 24
or 15 months, respectively [33]. Collectively, these observations have
fueled interest in studying the molecular interactions between the
epithelium and recruited stromal fibroblasts. Surprisingly, the
contribution of fibroblasts to ADM has not garnered the same
attention, and noncell autonomous signaling that drives ADM is not
well described.
ETS2 is a member of the ETS transcription factor family that
has been studied as a downstream regulator of RAS-mediated
transformation [34–37]. ETS2 also interacts specifically with mutantp53 to redirect promoter recruitment of p53, and further studies have
shown that ETS2 is crucial for mutant tp53 oncogenic functions
[38–40]. The ability of ETS2 to regulate both RAS- and
p53-mediated signaling places it at a crossroads between these two
powerful oncogenic signaling pathways that are misregulated in
pancreatic cancer. Previous studies have revealed that ETS2 also
regulates epithelial cell fate from the stromal compartment [41,42].
Specifically, deletion of Ets2 in the epithelium of mouse mammary
tumor models had no significant effect, whereas fibroblast-specific
Ets2 deletion led to markedly decreased tumor growth [42]. These
studies have established that fibroblast ETS2-mediated signaling is an
important regulator of the complex cross talk between stromal cells
and epithelial cells. ETS factors in general (especially ETS1 and
ETS2) are enriched in stromal cell populations in many cancers
through a variety of mechanisms [41,43–46].
In this report, we show that ETS2 signaling is activated in human
and mouse pancreatic fibroblasts during ADM. We further use
genetically engineered mouse models of ADM to demonstrate that
deletion of Ets-2 in fibroblasts leads to decreased acinar cell
transformation, decreased immune cell infiltration, and decreased
cytokine and chemokine production by fibroblasts. These results
define a fibroblast-specific ETS2-choreographed immune response
that leads to an immune-suppressive microenvironment during the
earliest stages of preneoplastic transformation of the pancreas.
Materials and Methods
Animal Strains, Husbandry, and Maintenance
The use of animals was in compliance with federal and Ohio State
University Laboratory Animal Resources regulations. Mist1KrasG12D;
Fsp-Cre; Ets2db/loxP and Mist1KrasG12D; Ets2db/loxP animals were generated
by crossing the previously described Mist1KrasG12D, FspCre, Ets-2loxP, and
Ets-2db strains [10,47–49].The experimentswere performedusing littermate
mice from a mixed C57BL/6; 129/Sv and FVBN genetic background.Multispectral Analysis of Dual-Color Immnohistrochemistry (IHC)
Dual-stained samples were imaged using the PerkinElmer's Vectra
multispectral slide analysis system. For the mouse samples, at least three
multispectral images per animal for at least three mice per genotype
(unless otherwise noted) were manually taken. For the human PDAC
Tissue Microarray, one field of interest per core was automatically
acquired. The image acquisition workflow consisted of the following: 1)
monochrome imaging of the entire slide, 2) RGB low-power imaging of
the tumor tissue using an inForm tissue finding algorithm, and 3)
multispectral high-power imaging of one field containing tumor
epithelium and stroma by means of an inFormHPF finding algorithm.
For quantification of the DAB staining, the multispectral images were
reviewed and analyzed using inForm Tissue Finder software. A pattern
recognition algorithm was used for processing as follows: 1) trainable tissue
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epithelium; 2) cell segmentation of the SMA-positive tissue category to
locate the subcellular compartments; and 3) scoring to bin the spectrally
unmixedDAB signal into four categories depending on the staining intensity
(0+, 1+, 2+, and 3+), providing data in percent. The H-score, which
ranges from 0 to 300, was calculated using following formula: [1 × (% cells
1+) + 2 × (% cells 2+) + 3 × (% cells 3+)]. Thus, H-score measures staining
intensity aswell as percentage of positive cells in a given cellular compartment.
Histology Analysis, Immunohistochemistry, and Immunofluor-
escent Staining
Dissected mouse pancreas tissues were fixed in 10%
neutral-buffered formalin solution for 48 hours and transferred to
70% ethanol. Tissues were processed, embedded in paraffin, cut in 5
μm sections on positively charged slides, deparaffinized, rehydrated,
and stained with hematoxylin and eosin (H&E).
For immunohistochemistry, all sections were stained using a Bond Rx
autostainer (Leica) unless otherwise noted.Briefly, slideswere baked at 65°C for
15 minutes, and automated software performed dewaxing, rehydration,
antigen retrieval, blocking,primary antibody incubation,postprimary antibody
incubation, detection (DAB or RED), and counterstaining using Bond
reagents (Leica). Samples were then removed from the machine, dehydrated
through ethanols and xylenes, mounted, and coverslipped. Antibodies for the
following markers were diluted in antibody diluent (Leica): rabbit anti-bodies
αSMA (1:1500, Abcam), Ki67 (1:100, Abcam), and amylase (1:400, CST),
ETS2 (SC-351) and rat antibodies cytokeratin 19 (TROMA-III) (1:150,
DSHB, University of Iowa), and F4/80 (1:50 Invitrogen).
For fluorescent immunostaining, following deparaffinization, rehy-
dration, and PBSwashes, sections were blocked with serum-free Protein
block (Dako) for 30 minutes at room temperature. Cells grown on
coverslips were fixed with 4% paraformaldehyde and permeabilized
with 100% ice-cold methanol prior to blocking. Tissue immunostain-
ing required antigen retrieval, which was performed in a steamer (Black
& Decker) using a 1× Target Retrieval solution (pH 6.0) (Dako).
Antibodies for the following markers were diluted in antibody diluent
(Dako) and applied overnight at 4°C: rabbit antibodies Ki67 (1:100,
Abcam) and amylase (1:400, CST), rat antibodies cytokeratin 19
(TROMA-III) (1:150, DSHB, University of Iowa) and cytokeratin 8
(TROMA-I) (1:300, DSHB, University of Iowa), and mouse antibody
α-SMA (1:400 Sigma). Secondary antibodies conjugated with Alexa
Fluor 488 and Alexa Fluor 594 were placed on tissue sections for 1 hour
at room temperature (1:300, Invitrogen). Nuclei were counterstained
using SlowFade Gold Antifade reagent with 4′,6-diamidino-2-pheny-
lindole (Invitrogen). Tissue sections for fluorescencemicroscopy images
were mounted with SlowFade Gold Antifade reagent with 4′,6-diami-
dino-2-phenylindole (Invitrogen) and coverslipped, and images were
obtained using an Eclipse E800 microscope (Nikon) equipped with a
CoolSNAP cf. monochrome digital camera Peltier cooled to 20°C
(Photometrics). All images were captured with MetaVue version 6.2r6
software (Universal Imaging Corp.) and resized and formatted with
Adobe Photoshop CS5 software (Adobe Systems Incorporated).
Chromatin Immunoprecipitation (ChIP) Assays
ChIPassayswereperformedas previously described [43].Briefly, cellswere
cross-linked for 10minutes with 1% formaldehyde and lysed. Chromatin
was collected and sonicated. Anti-Ets2 ChIP grade antibody (sc-351X) and
protein G agarose slurry (Millipore 16-266) were used to pull down
chromatin. After reverse cross-linking, DNA was recovered, purified, and
analyzed by reverse transcriptase polymerase chain reaction (RT-PCR).Pancreatic Fibroblast Isolation and Culture
Primary pancreatic fibroblasts were purified based on the following
protocol. Briefly, pancreata were dissected from 6-month-old mice,
minced, and digested with collagenase (0.5% Collagenase II,
120 Uml−1 DNase I in 1× PBS) shaking at 225 rpm for an hour
at 37°C. Collagenase was neutralized with 10% FBS-Dulbecco’s
modified Eagle’s medium. Digested tissue was resuspended in medium
and gravity purified for 10 minutes. Supernatants were aspirated, and
pellets were washed three times and subjected to two additional gravity
sedimentations and then seeded on tissue-culture dishes.
RNA, Microarray, and Real-Time PCR
RNA was harvested with Trizol according to the manufacturer's
instructions (Invitrogen). RNA quality and concentration were assessed
with Bioanalyser andNanodrop RNA 6000 nanoassays. RNA samples were
hybridized to Affymetrix GeneChipMouse genome 430 2.0 platform at the
Microarray Shared Resource Facility, Ohio State University Comprehensive
Cancer Center. The microarray data were deposited with Gene Expression
Omnibus (GEO) and can be viewed at http://www.ncbi.nlm.nih.gov/geo/
query/acc.cgi?token=afqbqaeoxbgltor&acc=GSE61707.
The RNA-sequencing data were deposited with GEO under Series
GSE76498 and can be viewed at http://www.ncbi.nlm.nih.gov/geo/
query/acc.cgi?token=mlwjyqiqplmfbyd&acc=GSE76498. Real-time
quantification of mRNA was performed using Roche Universal Primer
Library probes and probe-specific primers. Applied Biosystems StepO-
nePlus real time PCR machines were used. Normalization and target to
reference ratios were calculated according to the manufacturer's
instructions (Roche). Total RNA (1 μg) was converted to cDNA using
the Super-script Reverse Transcriptase kit (Invitrogen). List of
quantitative (q)RT-PCR and Roche Universal Probe library number is
indicated in the table below:Gene Name Forward Primer Reverse Primer Probe #hRpl4
AGCGTGGCT
GTCTCCTCTCGGACCCATCAAA
GGTGTCAA40hEts2
CCCCTGTGGCT
AACAGTTACAAAGGGAGCACA
GCAAACAGA20hGli1
CAGGGAGGAAA
GCAGACTGAACTGCTGCAGG
ATGACTGG76hGli2
ACTCCACACAC
GCGGAACCCACTGAAG
TTTTCCAGGATG16hGli3
TCAAACCCGAT
GAAGACCTCTTGTTCCTT
CGGGCTGTT26hStat3
CCTCTGCCGG
AGAAACAGCTGTCACTGTA
GAGCTGATGGAG1hJun
CCAAAGGATAGT
GCGATGTTTCTGTCCCTCTCC
ACTGCAAC19hMyc
CGGTTTTC
GGGGCTTTATGGCTCTTCCA
CCCTAGCC13hSox11
GAGCTGAGC
GAGATGATCGGAACACCAGGT
CGGAGAAGT19hMed1
AACACCCTCA
TTGGAAGCTGGGACACACTTC
AAATTGGAGAA2hp65
CGGGATGGC
TTCTATGAGGGGATGCGCT
GACTGATAGC1mRpl4
GATGAGCTGTAT
GGCACTTGGCTTGTGCAT
GGGCAGGTTA38mCcl3
TGCCCTTG
CTGTTCTTCTCTGTGGAATCTT
CCGGCTGTAG40mCcl4
AGGAGGAGCC
ACTTCAGGAGAGCAAGGACG
CTTCTCAGT73mCxcl4
AGCGGTGGTT
GCTGTCACTGGTGATGTG
CTTAAGATGGA82mCxcl5
TAGAGCCCC
AATCTCCACACGAGCTGGAGG
CTCATTGTG67mCxcl10 GCTGCCGTC TCTCACTGG 3(continued on next page)
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GTCCTACCTCCT
CCTGCTCATCAGCTCTCAA
CTCGTGACC60chipCcl4
CCACTCCATCT
CCCTCCTTTGAAAGTGAGGA
GTTCCTGACAGA3chipCxcl4
CACATCTCCAA
CCCCACAGCACGTAACTCC
AAAGCCACTG4chipCxcl5
GGCAAAGGG
TGCAAAGATTCAACTTCACAG
ATGACTCAGCA69chipCxcl10
CTCAGCGGT
GGATGAAGCGGACTCAGGG
AGGGAAACTC73hCcl3
TCTTCCTAACC
AAGCGAAGCGAAGCTTCT
GGACCCCTCA1hCcl4
CTCTCCAGCG
CTCTCAGCACCACAAAGTT
GCGAGGAAG40hCxcl4
ACTGAGATCCT
GCTGGAAGCAAGTGGCAGG
AGCAGCAA66hCxcl5
TGACACTTGT
GAAAAGGCTTGTAAGCAAAAATAG
AAATTCACAACCA52hCxcl10
GATGCAGTG
CTTCCAAGGATTGACATATACTCC
ATGTAGGGAAGTG34Statistics
Wilcoxon rank sum test and Student's t test were calculated using
R 3.0.1. The P values from Student's t tests are listed unless otherwise
specified. In all graphs, median, means (bar), and standard deviations
(lines) are denoted. Microarray data were processed by Robust
Multiarray Average method and analyzed using the moderated t test
approach [50]. P value of .05 was considered significant.
Results
Ets-2 Signaling Is Activated in Pancreatic Fibroblasts
Previous studies have shown that ETS2 levels increase in ductal
tumor cells with PDAC staging, but fibroblast ETS2 levels have yet to
be explored [51]. Dual-color IHC staining of normal pancreatic tissue,
pancreatitis tissue, and PDAC patient tissue for alpha-SMA and ETS2
was analyzed using the Vectra multispectral imaging system (Figure 1A,
see Materials And Methods). The analysis demonstrated that nuclear
ETS2 staining was significantly enriched in fibroblasts from both
pancreatitis and PDAC patient samples relative to normal pancreatic
controls (Figure 1B). Robust staining within acinar and ductal epithelial
cells in both normal and PDAC patient samples was also observed,
consistent with previous reports [51]. To further test the hypothesis that
ETS2 is activated in pancreatic fibroblasts, primary fibroblasts from
resected PDAC patient tumors were isolated, and mRNA expression of
Ets-2 was compared relative to other proto-oncogenic transcription
factors. Among the 10 transcription factors analyzed, only Ets-2 and
Gli1 showed significantly higher levels of mRNA in cancer-associated
fibroblasts relative to control pancreatic fibroblasts (Figure 1C). Gli1,
the nuclear effector ofHedgehog receptor signaling, has been previously
shown to be expressed by pancreatic cancer–associated fibroblasts
[52,53].
Fibroblast Ets-2 Is Upregulated Early and Late in Pancreatic
Tumorigenesis
SMA-ETS2 dual IHC was repeated in a cohort of LSL-KrasG12D/+;
LSL-Trp53R172H/+; Pdx-1-Cre (KPC) mice, demonstrating that ETS2
is activated in fibroblasts during early ADM and PanIN stages (2 weeks
of age) as well as in PDAC (4 months of age, Figure 2, A and B). Gene
set enrichment analysis (GSEA) of RNA sequencing of fibroblast
mRNA isolated from WT or KPC pancreata at the ADM stagedemonstrated that extracellular matrix remodeling and inflammatory
response pathways were highly enriched in KPC fibroblasts relative to
WT fibroblasts (Figure 2C). GSEA also identified ETS2-regulated
genes as an altered process in fibroblasts isolated from KPC mice
undergoing ADM (Figure 2C). This same ETS2 GSEA pathway
(“RYTTCCTG_V$ETS2_B” Broad Institute MSigDB gene set) was
significantly altered (P = 1.68 × 10−4) in the “activated stroma”
signature relative to “normal stroma” in the recent analysis of stromal
gene expression from 145 PDAC patients [33].
Fibroblast-Specific Deletion of Ets-2 Decreases
KrasG12D-Driven ADM
To determine the role ofEts2 signaling in epithelial-stromal cross talk
during ADM formation, we utilized the Mist1KrasG12D knock-in allele
in which oncogene expression originates in the acinar cell compartment
[10]. This model was combined with fibroblast-specific Fsp-Cre, which
was previously created and characterized extensively by our group
[41,42], and Ets2db/ loxP alleles to achieve efficient fibroblast-specific
conditional deletion of Ets-2.Mist1-KrasG12D; Ets2db/loxP (KE) control
mice and Mist1-KrasG12D; Fsp-Cre; Ets2db/loxP (KCE) experimental
mice were generated (Supplemental Figure 1A, see Materials and
Methods). Recombination of the Ets2loxP allele was confirmed in DNA
isolated from formalin-fixed, paraffin-embedded tissue sections by
genotyping PCR (Supplemental Figure 1B). IHC staining and
quantification using Vectra multispectral imaging of ETS2 in pancreatic
tissue sections fromKE andKCEmice confirmed in vivo deletion exclusively
in the fibroblast compartment (Supplemental Figure 1, C andD), whereas
ETS2 levels in thepancreatic epitheliumremainedunchanged (Supplemental
Figure 1E). Pancreatic fibroblasts were isolated from KE and KCEmice and
shown to be positive for fibroblast markers SMA and vimentin and negative
for epithelial markers cytokeratin 8 (CK8) or cytokeratin 19 (CK19) by
co-immunofluorescence (co-IF) (Supplemental Figure 1H). KCE fibroblast
cultures had lowerEts-2mRNArelative toKE (Supplemental Figure 1I), and
genotyping PCR was performed to show deletion of Ets-2loxP exclusively in
cultures isolated from Fsp-Cre–bearing mice (Supplemental Figure 1J).
To further confirm the fibroblast specificity of the Fsp1-Cre in the
pancreas, as previously demonstrated in normal mammary gland and
mammary tumors [41,42], we performed co-IF staining with the
macrophage marker F4/80 and ETS2. Consistent with our published
reports, there was no difference in ETS2 staining in F4/80
macrophages between KE and KCE mice (Supplemental Figure 1,
F and G). These collective results indicate that Ets-2 is efficiently
deleted in KCE mice exclusively in the fibroblast compartment and
this deletion is maintained under in vitro culture conditions.
Ets-2 specific deletion in stromal fibroblasts significantly
decreased the amount of ADM events, identified by ducts that
stain positive for ductal cell marker CK19 and acinar cell marker
β-amylase (Figure 3, A and B). CK19/Ki67 co-IF staining showed
that ductal cells in KCE mice had two-fold lower proliferation than
KE lesions (Figure 3, C and D; matched H&E in Supplemental
Figure 2A). Staining with apoptosis marker cleaved caspase 3 showed
increased numbers of apoptotic epithelial cells in the preneoplastic
ADMs in KCE mice relative to KE (Figure 3, E and F).Ets-2 Deleted Fibroblasts Are Viable and Maintain
an Activated Phenotype
Gene expression analysis of Ets2-intact and Ets2-deleted fibroblast
revealed that loss of Ets2 in pancreatic fibroblasts led to significant
changes (Supplemental Figure 3A and Supplemental Table 1).
Figure 1. Human pancreatic cancer associated fibroblasts activate Ets-2 signaling.(A) Dual-color IHC (ETS2, brown; SMA, red) of human
normal or PDAC Tissue Microarray. Insets show higher magnified view of representative areas. Black arrows indicate ETS2+/SMA+
fibroblasts. Scale bars 25 μm. (B) Quantification of ETS2 staining in SMA+ positive cells shown in A (red bar indicates mean). (C) qRT-PCR
analysis of proto-oncogenic transcription factors in pancreatic fibroblasts isolated from normal or PDAC patients (normalized to Rpl4,
represented as fold-change relative to normal fibroblast expression; n = 3; bars represent means ± Standard Deviation [SD]).
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downregulated in the KCE versus KE fibroblasts (Figure 4 A, P = .002).
However, in contrast to our findings in breast cancer [42], GSEA
indicated that pancreatic fibroblasts lacking Ets-2 maintained an
activated extracellular matrix (ECM) remodeling state, as there was no
significant difference between KCE and KE fibroblasts (Figure 4B; P =
.117 and false discovery rate [FDR] N 25%). In contrast, GSEA
identified that inflammatory responses were significantly affected by
Ets2 deletion in fibroblasts (Figure 4C, P b .001).Dual-color IHC staining of SMAandKi67 showed no difference in the
proliferation or total number of SMA-positive fibroblasts in KCE mice
compared to KE controls, demonstrating that differences in ADM
formation between KE and KCE mice were not due to decreased viability
or proliferation of Ets2-null fibroblasts (Figure 4D and Supplemental
Figure 3B, respectively). An important physiological function for activated
stromal fibroblasts is to form and remodel a collagen-rich extracellular
matrix. Masson's Trichrome staining revealed no significant difference in
the area of collagen-rich ECM between KCE and KE mice, consistent the
Figure 2. ETS2 is upregulated in PanIN and PDAC fibroblasts.(A) Dual-color IHC (ETS2, brown; SMA, red) of pancreata from KPC mice at
PanIN or PDAC stage. Insets show higher magnified view of representative areas. Black arrows indicate ETS2+/SMA+ fibroblasts. Scale
bars 25 μm. (B) Quantification of ETS2 staining in SMA+ positive cells shown in A (red bar indicates mean). (C) GSEA enrichment plots for
ECM remodeling, inflammation, and ETS2-regulated gene pathways in mouse WT or KPC pancreatic fibroblast cultures (n = 3).
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difference in angiogenesis pathways between KE and KCE fibroblasts
(Supplemental Figure 3C; P = .174 and FDR N 25%), and Meca-32
staining of endothelial cells demonstrated no significant differences between
control and ETS2-null tissue (Supplemental Figure 3D).
Ets-2 Deletion In Fibroblasts Alters the Immune Cell Infiltrate
during ADM
To explore the predicted changes in inflammatory responses upon
Ets2 deletion in pancreatic fibroblasts, antibodies for cell-type–specific
markers were used to test whether KE and KCE mice had different
infiltration of GR1-positive myeloid-derived suppressor cells (MDSCs),
F4/80-positive macrophages, FoxP3-positive Tregs, or CD8-positive
cytotoxic T cells. The results demonstrated that MDSCs, Tregs, and
macrophages were recruited to the stroma in KE mice, and all three cell
populations were significantly depleted in the KCE mice with Ets2
ablation (Figure 5, A–D and Supplemental Fig. 4, A and B, respectively).
Of note, recruitment ofMDSCs into the pancreatic stroma of KCEmice
was decreased by 100-fold compared to KEmice (Figure 5A). In contrast,
CD8+ cytotoxic T cells were increased two-fold in KCE mice compared
to KE controls (Figure 5,E and F). CD8+ cells were confirmed to be dual
positive for CD3 (Figure 5G; white arrows).
Ets-2 Directly Regulates Chemokine Expression in
Pancreatic Fibroblasts
GSEA revealed that chemokine and cytokine pathways were
significantly affected by Ets2 deletion (Figure 6A). Further in silicodissection of the chemokine and cytokine GSEA pathways showed
that 15 secreted factors were present on the leading edge analysis of
the pathways (Supplemental Table 2). The 15 ligands belonged to 3
subgroups: chemokine ligands, interleukins, and TNF superfamily
members (Supplemental Table 3). Using publically available data on
the Encyclopedia of DNA Elements consortium database, we used
ChIP-Seq data available for the closely related transcription factor
ETS1 (GEO accession GSM1003774 and GSM1003777) to identify
predicted ETS binding sites in the promoters of the 15 ligands. The
promoters of 9 of the 15 factors (60%) contained ETS1ChIP-Seq peaks
that are also predicted ETS2 binding sites (Supplemental Table 3). The
ETS2 binding sites were conserved in mice and human (Supplemental
Figure 5). Out of these nine, five factors (CCL3, CCL4, CXCL4,
CXCL5, CXCL10) are known to function in recruiting T cells,
macrophages, or MDSCs [54–58] (Supplemental Table 3).
Strikingly, real-time RT-PCR confirmed that mRNAs for all five
ligands were expressed in KE fibroblasts, whereas expression was not
detectable in cells with Ets2 deletion (Figure 6B). Furthermore, all
five ligands were expressed in human PDAC patient-derived cancer
associated fibroblasts (Figure 6C). ETS2 ChIP on chromatin from KE
and KCE pancreatic fibroblasts showed significant ETS2 enrichment
in ETS2-intact versus deleted fibroblasts (Figure 6D).
Discussion
The results presented here identify ETS signaling in fibroblasts as a
means of immune cell recruitment to ADM. ETS2 directly coordinates
a chemokine signature that alters the immune contexture at the early
Figure 3. Stromal ETS2 ablation decreases pancreatic ADM.(A and B) Dual-color IHC and quantitation for β-amylase (red) and CK19
(brown). Black arrows indicate ADM lesions. (C and D) Co-IF for CK19 (red) and Ki67 (green) and quantification of percentage of
proliferating CK19+ cells, indicated by white arrows. (E and F) IHC for cleaved caspase 3 (brown) and quantification of percentage of
epithelial cells undergoing apoptosis. All scale bars 25 μm (n = 7; red bar indicates mean).
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production of key chemokines in fibroblasts, resulting in decreased
infiltration of macrophage, MDSC, and Treg populations while
increasing CD8 T cells.
The stroma undergoes a dramatic expansion in concert with the
stepwise development of pancreatic cancer, suggesting that the stroma
is an active partner in disease initiation and progression. However,
characterizing the complex interactions between the pancreatic
epithelium and the adjacent stroma has proved difficult, as recent
reports have highlighted the degree of heterogeneity that exists in the
pancreatic stroma. In particular, depletion of SMA-positive cells
accelerated pancreatic cancer, whereas depletion of FAP-positive cells
slowed tumor growth [29,31]. Interestingly, both studies identified
immune cell subpopulations that dynamically interact with stromal
fibroblasts. Tumors depleted for SMA-positive cells were responsive
to α-CTLA-4 therapy, which functions by altering T-cell activation
[31]. Tumors depleted for FAP-positive cells were dependent on bothCD4 and CD8 T-cell populations, and fibroblast depletion
synergized with α-PD-1 and α-CTLA-4 immune checkpoint therapy
[29]. These studies indicate that fibroblast-immune cell cross talk is
complex, and our results establish that ETS2 is responsible for the
production of several key immunomodulatory chemokines and
cytokines. We propose that ETS2 is activated in fibroblasts early
during epithelial transformation of the pancreas and helps to establish
an immune microenvironment that is conducive to increased
ADM formation.
The function of ETS2-mediated signaling in pancreatic fibroblasts
is to modulate the presence of immune cells in the preneoplastic
stroma and is a phenotype that is distinct from its role in mammary
fibroblasts. Our previous studies in mammary tumor growth have
shown that the primary function of ETS2 in the fibroblast
compartment is to promote angiogenesis, which was not observed
in the pancreas [41,42]. Furthermore, differences in chemokine and
cytokine gene expression and changes in immune cell populations
Figure 4. Ets-2 deletion does not affect fibroblast proliferation or collagen deposition.(A–C) GSEA enrichment plots for Ets2-regulated
genes, ECM remodeling, and inflammation pathways in KE and KCE fibroblasts (n = 3). (D and E) Dual-color IHC of SMA (red) and Ki67
(brown) and quantification showing the percentage of proliferating SMA+ cells, indicated by black arrows. (F and G) Masson's Trichrome
stain and quantification of the percent area of collagen staining (n = 7; red bar indicates mean).
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tumor stroma [41,42]. Thus, ETS2 alters the fibroblast transcriptome
in a tissue-specific fashion and subsequently modulates the
communication between the epithelial cell and its microenvironment
in distinct manner. This is consistent with the observation that
fibroblasts maintain a complex positional memory that drives specific
gene expression patterns based on their topographical location [59].
These results also highlight the diversity of stromal fibroblasts and
show that a more detailed understanding of the signaling networks
within fibroblasts derived from cancers of different origins is required
to more precisely understand epithelial-fibroblast cross talk.
The most striking change in immune cell recruitment upon loss of
ETS2 signaling from the fibroblasts was in the immunosuppressive
MDSC population. These cells are recruited early during pancreatic
tumorigenesis, as they are present at the ADM/PanIN stage and
progressively increase during malignant progression [22,60]. Addi-
tionally, MDSC levels positively correlate with FoxP3-positive Treg
numbers in pancreatic cancer, consistent with our results at the ADMstage [61]. Further functional studies into MDSCs in pancreatic
cancer has revealed that pancreatic cancer–associated stellate cells
secrete factors that drive MDSC differentiation, which in turn
suppresses CD8-positive T-cell proliferation [62]. It has also been
observed that MDSC and CD8-positive populations are present
in a nearly mutually exclusive relationship in both PanIN and
PDAC, suggesting that early host immunosuppressive responses are
able to impede T-cell infiltration [22]. The decrease in MDSCs in
Ets2-deleted pancreata may open the door for recruitment of
CD8-positive T cells. These cells have previously been characterized
for their ability to eliminate tumor cells during pancreatic cancer
development and progression [63], and patients who have increased
CD8-positive populations have improved prognosis [64,65]. The
genetic data presented here suggest that ETS2 is involved in the
interactions between fibroblasts and immunosuppressive cells that
may contribute to KrasG12D epithelial cell proliferation indirectly.
KrasG12D epithelial cell proliferation may also be directly affected
by ETS2 in fibroblasts, as chemokines are a major conduit of
Figure 5. Ets-2 fibroblast deletion alters the pancreatic immune microenvironment.(A and B) IHC for GR1 (brown) and quantification of
positive cells per mm2. (C and D) IHC for FoxP3 (brown) and quantification of positive cells per mm2. (E and F) Co-IF for CD8 (red) and CD3
(green) and quantification of CD8-positive cells per mm2. (G) Insets show higher magnified view of representative areas; white arrows
indicate CD3+/CD8+ cells. All scale bars 25 μm (n = 7; red bar indicates mean).
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Figure 6. Ets-2 directly regulates chemokine and cytokine production.(A) GSEA enrichment plots for cytokine and chemokine pathways in
KE versus KCE fibroblasts (n = 3). (B) qRT-PCR of secreted factors in KE and KCE mouse fibroblasts (normalized to Rpl4, represented as
fold-change relative to ETS2WT expression; n = 3; bars represent means ± SD; N.E. = not expressed). (C) qRT-PCR of secreted factors in
human PDAC-derived CAF cultures (normalized to Rpl4, represented as fold-change relative to normal fibroblast expression; n = 3; bars
represent means ± SD). (D) Relative enrichment for ETS2 binding to the promoters of indicated genes in KE and KCE mouse fibroblasts
(n = 5; bars represent means ± SD).
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targets CCL3, CCL4, CXCL5, and CXCL10 have all been linked to
increased tumor cell proliferation in a variety of cancers [66–70].
ETS2 signaling may also play an important signal transduction role
from within the epithelial cell, given its role downstream of
RAS-MAPK and mutant P53 signaling pathways [38,39,71–73].Thus, ETS2 could present an overlap between KRAS and p53
signaling, but further biochemical work will be required to pin down
the interworkings of this signaling network within the pancreatic
tumor cell. Targeting ETS2 signaling may be beneficial to inhibit
both epithelial cell intrinsic oncogenic mechanisms as well as the
fibroblast-driven immune-modulatory effects defined herein.
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doi.org/10.1016/j.neo.2016.07.006.
Conflict of Interest
The authors report no conflicts of interest.
Acknowledgements
We acknowledge Jason Bice, Daphne Bryant, Nicole Drummond,
and Lisa Rawahneh from the OSU Solid Tumor Biology Histology
Core for their technical support. We also thank Chelsea K. Martin
for assisting in initial analysis of pancreatic tumor histology. We
acknowledge the OSUCCC Genomics, Microscopy, Transgenic/
Knockout, Target Validation, Analytic Cytometry, Bioinformatics,
and Biostatistics Shared Resources. This study was supported by
National Institutes of Health grants PO1 CA097189 (M. C. O.
and G. L.), NRSA F31 CA189757 (J. R. P.), and R01 CA124586
(S. F. K.). This work was also supported by the Pelotonia Fellowship
Program (J. R. P.). Any opinions, findings, and conclusions
expressed in this material are those of the author(s) and do not
necessarily reflect those of the Pelotonia Fellowship Program.
References
[1] Hidalgo M (2010). Pancreatic cancer. N Engl J Med 362(17), 1605–1617.
[2] Howlader N, Noone AM, KrapchoM, Garshell J, Miller D, Altekruse SF, Kosary
CL, Yu M, Ruhl J, and Tatalovich Z, et al (2015). SEER Cancer Statistics
Review, 1975-2012. Bethesda, MD: National Cancer Institute; 2015 [http://
seer.cancer.gov/csr/1975_2012/, based on November 2014 SEER data submis-
sion, posted to the SEER web site].
[3] Almoguera C, Shibata D, Forrester K, Martin J, Arnheim N, and Perucho M
(1988). Most human carcinomas of the exocrine pancreas contain mutant c-K-ras
genes. Cell 53(4), 549–554.
[4] Barton CM, Staddon SL, Hughes CM, Hall PA, O'Sullivan C, Kloppel G, Theis
B, Russell RC, Neoptolemos J, and Williamson RC, et al (1991). Abnormalities
of the p53 tumour suppressor gene in human pancreatic cancer. Br J Cancer
64(6), 1076–1082.
[5] Scarpa A, Capelli P, Mukai K, Zamboni G, Oda T, Iacono C, and Hirohashi S
(1993). Pancreatic adenocarcinomas frequently show p53 gene mutations. Am J
Pathol 142(5), 1534–1543.
[6] Kanda M, Matthaei H, Wu J, Hong SM, Yu J, Borges M, Hruban RH, Maitra A,
Kinzler K, and Vogelstein B, et al (2012). Presence of somatic mutations in most
early-stage pancreatic intraepithelial neoplasia. Gastroenterology 142(4), 730–733 [e9].
[7] Hezel AF,KimmelmanAC, Stanger BZ,BardeesyN, andDepinhoRA (2006).Genetics
and biology of pancreatic ductal adenocarcinoma. Genes Dev 20(10), 1218–1249.
[8] Grippo PJ, Nowlin PS, Demeure MJ, Longnecker DS, and Sandgren EP (2003).
Preinvasive pancreatic neoplasia of ductal phenotype induced by acinar cell
targeting of mutant Kras in transgenic mice. Cancer Res 63(9), 2016–2019.
[9] Habbe N, Shi G, Meguid RA, Fendrich V, Esni F, Chen H, Feldmann G, Stoffers
DA, Konieczny SF, and Leach SD, et al (2008). Spontaneous induction of murine
pancreatic intraepithelial neoplasia (mPanIN) by acinar cell targeting of oncogenic
Kras in adult mice. Proc Natl Acad Sci U S A 105(48), 18913–18918.
[10] TuvesonDA,Zhu L, Gopinathan A,Willis NA, Kachatrian L,GrochowR, Pin CL,
Mitin NY, Taparowski EJ, and Gimotty PA, et al (2006). Mist1-KrasG12D
knock-in mice develop mixed differentiation metastatic exocrine pancreatic
carcinoma and hepatocellular carcinoma. Cancer Res 66(1), 242–247.
[11] De La OJ, Emerson LL, Goodman JL, Froebe SC, Illum BE, Curtis AB, and
Murtaugh LC (2008). Notch and Kras reprogram pancreatic acinar cells to ductal
intraepithelial neoplasia. Proc Natl Acad Sci U S A 105(48), 18907–18912.
[12] Kopp JL, von Figura G, Mayes E, Liu FF, Dubois CL, Morris JP, Pan FC,
Akiyama H, Wright CV, and Jensen K, et al (2012). Identification of
Sox9-dependent acinar-to-ductal reprogramming as the principal mechanism for
initiation of pancreatic ductal adenocarcinoma. Cancer Cell 22(6), 737–750.
[13] Eser S, Reiff N, Messer M, Seidler B, Gottschalk K, Dobler M, Hieber M,
Arbeiter A, Klein S, and Kong B, et al (2013). Selective requirement of
PI3K/PDK1 signaling for Kras oncogene-driven pancreatic cell plasticity and
cancer. Cancer Cell 23(3), 406–420.[14] Zhang Y, Morris JP, Yan W, Schofield HK, Gurney A, Simeone DM, Millar SE,
Hoey T, Hebrok M, and Pasca di Magliano M (2013). Canonical wnt signaling is
required for pancreatic carcinogenesis. Cancer Res 73(15), 4909–4922.
[15] Liou GY, Doppler H, Necela B, Krishna M, Crawford HC, Raimondo M, and
Storz P (2013). Macrophage-secreted cytokines drive pancreatic acinar-to-ductal
metaplasia through NF-kappaB and MMPs. J Cell Biol 202(3), 563–577.
[16] Shi G, DiRenzo D, Qu C, Barney D, Miley D, and Konieczny SF (2013).
Maintenance of acinar cell organization is critical to preventing Kras-induced
acinar-ductal metaplasia. Oncogene 32(15), 1950–1958.
[17] Zhang W, Nandakumar N, Shi Y, Manzano M, Smith A, Graham G, Gupta S,
Vietsch EE, Laughlin SZ, and Wadhwa M, et al (2014). Downstream of mutant
KRAS, the transcription regulator YAP is essential for neoplastic progression to
pancreatic ductal adenocarcinoma. Sci Signal 7(324), ra42.
[18] Maitra A, Fukushima N, Takaori K, and Hruban RH (2005). Precursors to
invasive pancreatic cancer. Adv Anat Pathol 12(2), 81–91.
[19] Zhu L, Shi G, Schmidt CM, Hruban RH, and Konieczny SF (2007). Acinar cells
contribute to the molecular heterogeneity of pancreatic intraepithelial neoplasia.
Am J Pathol 171(1), 263–273.
[20] Parsa I, Longnecker DS, Scarpelli DG, Pour P, Reddy JK, and Lefkowitz M
(1985). Ductal metaplasia of human exocrine pancreas and its association with
carcinoma. Cancer Res 45(3), 1285–1290.
[21] Remmers N, Anderson JM, Linde EM, DiMaio DJ, Lazenby AJ, Wandall HH,
Mandel U, Clausen H, Yu F, and Hollingsworth MA (2013). Aberrant
expression of mucin core proteins and o-linked glycans associated with
progression of pancreatic cancer. Clin Cancer Res 19(8), 1981–1993.
[22] Clark CE, Hingorani SR, Mick R, Combs C, Tuveson DA, and Vonderheide
RH (2007). Dynamics of the immune reaction to pancreatic cancer from
inception to invasion. Cancer Res 67(19), 9518–9527.
[23] Collins MA, Bednar F, Zhang Y, Brisset JC, Galban S, Galban CJ, Rakshit S,
Flannagan KS, Adsay NV, and Pasca di Magliano M, et al (2012). Oncogenic
Kras is required for both the initiation and maintenance of pancreatic cancer in
mice. J Clin Invest 122(2), 639–653.
[24] Korc M (2007). Pancreatic cancer–associated stroma production. Am J Surg
194(4 Suppl.), S84–S86.
[25] Feig C, Gopinathan A, Neesse A, Chan DS, Cook N, and Tuveson DA (2012).
The pancreas cancer microenvironment. Clin Cancer Res 18(16), 4266–4276.
[26] Neesse A, Algul H, Tuveson DA, and Gress TM (2015). Stromal biology and
therapy in pancreatic cancer: a changing paradigm. Gut 64(9), 1476–1484.
[27] Erkan M, Hausmann S, Michalski CW, Fingerle AA, Dobritz M, Kleeff J, and
Friess H (2012). The role of stroma in pancreatic cancer: diagnostic and
therapeutic implications. Nat Rev Gastroenterol Hepatol 9(8), 454–467.
[28] Perez-ManceraPA,GuerraC,BarbacidM,andTuvesonDA(2012).Whatwehave learned
about pancreatic cancer from mouse models. Gastroenterology 142(5), 1079–1092.
[29] Feig C, Jones JO, Kraman M, Wells RJ, Deonarine A, Chan DS, Connell CM,
Roberts EW, Zhao Q, and Caballero OL, et al (2013). Targeting CXCL12 from
FAP-expressing carcinoma-associated fibroblasts synergizes with anti–PD-L1 immu-
notherapy in pancreatic cancer. Proc Natl Acad Sci U S A 110(50), 20212–20217.
[30] Rhim AD, Oberstein PE, Thomas DH, Mirek ET, Palermo CF, Sastra SA,
Dekleva EN, Saunders T, Becerra CP, and Tattersall IW, et al (2014). Stromal
elements act to restrain, rather than support, pancreatic ductal adenocarcinoma.
Cancer Cell 25(6), 735–747.
[31] Ozdemir BC, Pentcheva-Hoang T, Carstens JL, Zheng X,Wu CC, Simpson TR,
Laklai H, Sugimoto H, Kahlert C, and Novitskiy SV, et al (2014). Depletion of
carcinoma-associated fibroblasts and fibrosis induces immunosuppression and
accelerates pancreas cancer with reduced survival. Cancer Cell 25(6), 719–734.
[32] Fujita H, Ohuchida K, Mizumoto K, Nakata K, Yu J, Kayashima T, Cui L, Manabe
T,OhtsukaTanakaM (2010). alpha-Smoothmuscle actin expressing stroma promotes
an aggressive tumor biology in pancreatic ductal adenocarcinoma. Pancreas .
[33] Moffitt RA, Marayati R, Flate EL, Volmar KE, Loeza SG, Hoadley KA, Rashid
NU, Williams LA, Eaton SC, Chung AH, and Smyla JK, et al (2015). Virtual
microdissection identifies distinct tumor- and stroma-specific subtypes of
pancreatic ductal adenocarcinoma. 47(10), 1168–1178.
[34] Hollingsworth MA, Yeh JJ, Yang BS, Hauser CA, Henkel G, Colman MS, Van
Beveren C, Stavey KJ, Hume DA, Maki RA, and Ostrowski MC (1996).
Ras-mediated phosphorylation of a conserved threonine residue enhances the
transactivation activities of c-Ets1 and c-Ets2. Nat Genet 16(2), 538–547.
[35] Patton SE, Martin ML, Nelsen LL, Fang X, Mills GB, Bast Jr RC, and
OStrowski Jr MC (1998). Activation of the ras-mitogen–activated protein kinase
pathway and phosphorylation of ets-2 at position threonine 72 in human ovarian
cancer cell lines. Cancer Res 58(10), 2253–2259.
552 Fibroblast ETS2 Coordinates ADM Immune Cell Recruitment Pitarresi et al. Neoplasia Vol. 18, No. 9, 2016[36] Foulds CE, Nelson ML, Blaszczak AG, and Graves BJ (2004).
Ras/mitogen-activated protein kinase signaling activates Ets-1 and Ets-2 by
CBP/p300 recruitment. Mol Cell Biol 24(24), 10954–10964.
[37] Kabbout M, Dakhlallah D, Sharma S, Bronisz A, Srinivasan R, Piper M, Marsh
CB, and Ostrowski MC (2014). MicroRNA 17-92 cluster mediates ETS1 and
ETS2-dependent RAS-oncogenic transformation. PLoS One 9(6)e100693.
[38] Do PM, Varanasi L, Fan S, Li C, Kubacka I, Newman V, Chauhan K, Daniels
SR, Boccetta M, and Garrett MR, et al (2012). Mutant p53 cooperates with
ETS2 to promote etoposide resistance. Genes Dev 26(8), 830–845.
[39] Xiong S, Tu H, Kollareddy M, Pant V, Li Q, Zhang Y, Jackson JG, Suh YA,
Elizondo-Fraire AC, and Yang P, et al (2014). Pla2g16 phospholipase mediates
gain-of-function activities of mutant p53. Proc Natl Acad Sci U S A 111(30),
11145–11150.
[40] Kollareddy M, Dimitrova E, Vallabhaneni KC, Chan A, Le T, Chauhan KM,
Carrero ZI, Ramakrishnan G, Watabe K, and Haupt Y, et al (2015). Regulation
of nucleotide metabolism by mutant p53 contributes to its gain-of-function
activities. Nat Commun 6, 7389.
[41] Trimboli AJ, Cantemir-Stone CZ, Li F, Wallace JA, Merchant A, Creasap N,
Thompson JC, Caserta E, Wang H, and Chong JL, et al (2009). Pten in stromal
fibroblasts suppresses mammary epithelial tumours. Nature 461(7267),
1084–1091.
[42] Wallace JA, Li F, Balakrishnan S, Cantemir-Stone CZ, Pecot T, Martin C,
Kladney RD, Sharma SM, Trimboli AJ, and Fernandez SA, et al (2013). Ets2 in
tumor fibroblasts promotes angiogenesis in breast cancer. PLoS One 8(8)e71533.
[43] Bronisz A, Godlewski J, Wallace JA, Merchant AS, Nowicki MO, Mathsyaraja
H, Srinivasan R, Trimboli AJ, Martin CK, and Li F, et al (2012).
Reprogramming of the tumour microenvironment by stromal PTEN-regulated
miR-320. Nat Cell Biol 14(2), 159–167.
[44] Man AK, Young LJ, Tynan JA, Lesperance J, Egeblad M, Werb Z, Hauser CA,
Muller WJ, CArdiff RD, and Oshima RG (2003). Ets2-dependent stromal
regulation of mouse mammary tumors. Mol Cell Biol 23(23), 8614–8625.
[45] Behrens P, Mathiak M, Mangold E, Kirdorf S, Wellmann A, Fogt F, Rothe M,
Florin A, and Wernert N, et al (2003). Stromal expression of
invasion-promoting, matrix-degrading proteases MMP-1 and -9 and the Ets 1
transcription factor in HNPCC carcinomas and sporadic colorectal cancers. Int J
Cancer 107(2), 183–188.
[46] Behrens P, Rothe M, Wellmann A, Krischler J, and Wernert N (2001). The
Ets-1 transcription factor is up-regulated together with MMP 1 and MMP 9 in
the stroma of pre-invasive breast cancer. J Pathol 194(1), 43–50.
[47] Trimboli AJ, Fukino K, de Bruin A, Wei G, Shen L, Tanner SM, Cresap N,
Rosol TJ, Robinson ML, and Eng C, et al (2008). Direct evidence for
epithelial-mesenchymal transitions in breast cancer. Cancer Res 68(3), 937–945.
[48] Wei G, Srinivasan R, Cantemir-Stone CZ, Sharma SM, Santhanam R,Weinstein
M, Muthusamy N, Man AK, Oshima RG, and Leone G, et al (2009). Ets1 and
Ets2 are required for endothelial cell survival during embryonic angiogenesis.
Blood 114(5), 1123–1130.
[49] Yamamoto H, Flannery ML, Kupriyanov S, Pearce J, McKercher SR, Henkel
GW, Maki RA, Werb Z, and Oshima RG, et al (1998). Defective trophoblast
function in mice with a targeted mutation of Ets2. Genes Dev 12(9), 1315–1326.
[50] Yu L, Gulati P, Fernandez S, Pennell M, Kirschner L, and Jarjoura D (2011).
Fully moderated T-statistic for small sample size gene expression arrays. Stat Appl
Genet Mol Biol 10(1).
[51] Ito Y, Miyoshi E, Takeda T, Sakon M, Ihara S, Tsujimoto M, and Matsuura N,
et al (2002). Ets-2 overexpression contributes to progression of pancreatic
adenocarcinoma. Oncol Rep 9(4), 853–857.
[52] Walter K,OmuraN,Hong SM,GriffithM, Vincent A, BorgesM, andGogginsM,
et al (2010). Overexpression of smoothened activates the sonic hedgehog signaling
pathway in pancreatic cancer-associated fibroblasts. Clin Cancer Res 16(6),
1781–1789.
[53] YauchRL,Gould SE, Scales SJ, Tang T, TianH, AhnCP,Marshall D, Fu L, Januario
T, and Kallop D, et al (2008). A paracrine requirement for hedgehog signalling in
cancer. Nature 455(7211), 406–410.
[54] Ajuebor MN, Hogaboam CM, Le T, Proudfoot AE, and Swain MG (2004).
CCL3/MIP-1alpha is pro-inflammatory in murine T cell–mediated hepatitis by
recruiting CCR1-expressing CD4(+) T cells to the liver. Eur J Immunol 34(10),
2907–2918.
[55] Burger JA, Quiroga MP, Hartmann E, Burkle A, Wierda WG, Keating MJ, and
Rosenwald A, et al (2009). High-level expression of the T-cell chemokines CCL3and CCL4 by chronic lymphocytic leukemia B cells in nurselike cell cocultures
and after BCR stimulation. Blood 113(13), 3050–3058.
[56] Balamayooran G, Batra S, Cai S, Mei J, Worthen GS, Penn AL, and Jeyaseelan S
(2012). Role of CXCL5 in leukocyte recruitment to the lungs during secondhand
smoke exposure. Am J Respir Cell Mol Biol 47(1), 104–111.
[57] Petrovic-Djergovic D, Popovic M, Chittiprol S, Cortado H, Ransom RF, and
Partida-Sanchez S (2015). CXCL10 induces the recruitment of monocyte-derived
macrophages into kidney, which aggravate puromycin aminonucleoside nephrosis.
Clin Exp Immunol 180(2), 305–315.
[58] Srivastava K, Cockburn IA, Swaim A, Thompson LE, Tripathi A, Fletcher CA,
Shirk EM, Sun H, Kowalska MA, and Fox-Talbot K, et al (2008). Platelet factor
4 mediates inflammation in experimental cerebral malaria. Cell Host Microbe
4(2), 179–187.
[59] Chang HY, Chi JT, Dudoit S, Bondre C, van de Rijn M, Botstein D, and Brown
PO (2002). Diversity, topographic differentiation, and positional memory in
human fibroblasts. Proc Natl Acad Sci U S A 99(20), 12877–12882.
[60] Pylayeva-Gupta Y, Lee KE, Hajdu CH, Miller G, and Bar-Sagi D (2012).
Oncogenic Kras-induced GM-CSF production promotes the development of
pancreatic neoplasia. Cancer Cell 21(6), 836–847.
[61] Gabitass RF, Annels NE, Stocken DD, Pandha HA, and Middleton GW (2011).
Elevated myeloid-derived suppressor cells in pancreatic, esophageal and gastric
cancer are an independent prognostic factor and are associated with significant
elevation of the Th2 cytokine interleukin-13. Cancer Immunol Immunother
60(10), 1419–1430.
[62] Mace TA, Ameen Z, Collins A,Wojcik S, Mair M, Young GS, Fuchs JR, Eubank
TD, Frankel WL, and Bekaii-Saab T, et al (2013). Pancreatic cancer-associated
stellate cells promote differentiation of myeloid-derived suppressor cells in a
STAT3-dependent manner. Cancer Res 73(10), 3007–3018.
[63] Wormann SM, Diakopoulos KN, Lesina M, and Algul H (2014). The immune
network in pancreatic cancer development and progression. Oncogene 33(23),
2956–2967.
[64] Ademmer K, Ebert M, Muller-Ostermeyer F, Friess H, Buchler MW, Schubert
W, and Malfertheiner P, et al (1998). Effector T lymphocyte subsets in human
pancreatic cancer: detection of CD8 + CD18+ cells and CD8 + CD103+ cells
by multi-epitope imaging. Clin Exp Immunol 112(1), 21–26.
[65] Fukunaga A, Miyamoto M, Cho Y, Murakami S, Kawarada Y, Oshikiri T, Kato
K, Kurokawa T, Suzuoki M, and Nakakubo Y, et al (2004). CD8+
tumor-infiltrating lymphocytes together with CD4+ tumor-infiltrating lympho-
cytes and dendritic cells improve the prognosis of patients with pancreatic
adenocarcinoma. Pancreas 28(1), e26–e31.
[66] Tsai SC, Lin SJ, Lin CJ, Chou YC, Lin JH, Yeh TH, Chen MR, Huang LM, Lu
MY, and Huang YC, et al (2013). Autocrine CCL3 and CCL4 induced by the
oncoprotein LMP1 promote Epstein-Barr virus–triggered B cell proliferation. J
Virol 87(16), 9041–9052.
[67] Lentzsch S, Gries M, Janz M, Bargou R, Dorken B, and Mapara MY (2003).
Macrophage inflammatory protein 1-alpha (MIP-1 alpha) triggers migration and
signaling cascades mediating survival and proliferation in multiple myeloma
(MM) cells. Blood 101(9), 3568–3573.
[68] Zheng J, Zhu X, and Zhang J (2014). CXCL5 knockdown expression inhibits
human bladder cancer T24 cells proliferation and migration. Biochem Biophys Res
Commun 446(1), 18–24.
[69] Kawamura M, Toiyama Y, Tanaka K, Saigusa S, Okugawa Y, Hiro J, Uchida K,
Mohri Y, Inoue Y, and Kusunoki M, et al (2012). CXCL5, a promoter of cell
proliferation, migration and invasion, is a novel serum prognostic marker in
patients with colorectal cancer. Eur J Cancer 48(14), 2244–2251.
[70] Maru SV, Holloway KA, Flynn G, Lancashire CL, Loughlin AJ, Male DK, and
Romero IA (2008). Chemokine production and chemokine receptor expression
by human glioma cells: role of CXCL10 in tumour cell proliferation.
J Neuroimmunol 199(1–2), 35–45.
[71] Wasylyk B, Hagman J, and Gutierrez-Hartmann A (1998). Ets transcription
factors: nuclear effectors of the Ras-MAP-kinase signaling pathway. Trends Biochem
Sci 23(6), 213–216.
[72] Sharrocks AD (2001). The ETS-domain transcription factor family. Nat Rev Mol
Cell Biol 2(11), 827–837.
[73] Zhu J, Sammons MA, Donahue G, Dou Z, Vedadi M, Getlik M,
Barsyte-Lovejoy D, Alawar R, Katona BW, and Shilatifard A, et al (2015).
Gain-of-function p53 mutants co-opt chromatin pathways to drive cancer
growth. Nature 525(7568), 206–211.
